撒哈拉以南非洲低收入地区孕产妇B族链球菌免疫接种的成本效益
研究采用决策树模型(含马尔可夫节点)模拟婴儿终生,比较常规产前保健中孕产妇免疫接种与不接种,覆盖37个按经济卫生资源及既往公共卫生表现聚类国家中的四个代表国(几内亚比绍、乌干达、尼日利亚、加纳)。当疫苗覆盖血清型效力为70%、接种率等于产前检查≥4次(ANC4)比例时,可预防约三分之一B族链球菌病例和死亡;每剂7美元时,每避免一个DALY成本为320–573美元,低于人均GDP。结论认为在撒哈拉以南非洲低收入地区可能具成本效益。
要点
- 在ANC4为50%的乌干达和尼日利亚,可预防约三分之一B族链球菌病例和死亡。
- 每剂7美元时,几内亚比绍、尼日利亚和加纳每避免一个DALY成本320–350美元,低于人均GDP一半。
- 乌干达每避免一个DALY成本573美元;若疫苗预防小部分死产则更具成本效益。
核心结论
- 孕产妇B族链球菌免疫接种在撒哈拉以南非洲低收入地区可能具有成本效益,成本效益比与近期引入的其他疫苗相似。
- 引入具有成本效益的疫苗接种成本取决于疾病发病率和疫苗效力。
研究设计与样本
- 决策树模型,含马尔可夫节点以模拟婴儿终生,比较常规产前保健中孕产妇免疫接种与不接种。
- 37个国家按经济卫生资源和既往公共卫生表现聚类,从四个聚类中各选一个代表国:几内亚比绍、乌干达、尼日利亚和加纳。
- 疫苗覆盖血清型的效力范围设为50%至90%。
- 模型预测早发型和晚发型B族链球菌病例与死亡、伤残调整生命年(DALY)、医疗费用(2014年美元)及成本效益。
- 估计满足两个成本效益基准(0.5倍GDP和人均GDP/DALY)的最大每剂疫苗接种成本,覆盖不同疾病发病率(报告值和漏报调整值)及疫苗效力范围。
主要发现
- 接种率等于产前检查≥4次(ANC4)孕妇比例、血清型特异性疫苗效力70%时,乌干达和尼日利亚(ANC4=50%)可预防约三分之一B族链球菌病例和死亡。
- 几内亚比绍(ANC4=65%)可预防42–43%的B族链球菌病例和死亡,加纳(ANC4=87%)可预防55–57%。
- 每剂7美元时,几内亚比绍、尼日利亚和加纳每避免一个DALY成本为320–350美元,低于这些国家人均GDP的一半。
- 乌干达(病死率最低)每避免一个DALY成本为573美元。
- 若疫苗预防小部分死产,则更具成本效益;敏感性分析中每剂疫苗接种成本、疾病发病率和病死率为每DALY成本的关键驱动因素。
关键数值与推荐
- 成本效益基准为每DALY成本不超过0.5倍GDP和不超过人均GDP。
- 疫苗覆盖血清型效力范围50%–90%,主要分析采用70%。
- 接种率等于ANC4比例(乌干达和尼日利亚50%,几内亚比绍65%,加纳87%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A maternal group B streptococcal (GBS) vaccine could prevent neonatal sepsis and meningitis. Its cost-effectiveness in low-income sub-Saharan Africa, a high burden region, is unknown. METHODS: We used a decision tree model, with Markov nodes to project infants' lifetimes, to compare maternal immunization delivered through routine antenatal care with no immunization. 37 countries were clustered on the basis of economic and health resources and past public health performance. Vaccine efficacy for covered serotypes was ranged from 50% to 90%. The model projected EOGBS (early-onset) and LOGBS (late-onset) cases and deaths, disability-adjusted life years (DALYs), healthcare costs (2014 US$), and cost-effectiveness for a representative country in each of the four clusters: Guinea-Bissau, Uganda, Nigeria, and Ghana. Maximum vaccination costs/dose were estimated to meet two cost-effectiveness benchmarks, 0.5 GDP and GDP per capita/DALY, for ranges of disease incidence (reported and adjusted for under-reporting) and vaccine efficacy. RESULTS: At coverage equal to the proportion of pregnant women with≥4 antenatal visits (ANC4) and serotype-specific vaccine efficacy of 70%, maternal GBS immunization would prevent one-third of GBS cases and deaths in Uganda and Nigeria, where ANC4 is 50%, 42-43% in Guinea-Bissau (ANC4=65%), and 55-57% in Ghana (ANC4=87%). At a vaccination cost of $7/dose, maternal immunization would cost $320-$350/DALY averted in Guinea-Bissau, Nigeria, and Ghana, less than half these countries' GDP per capita. In Uganda, which has the lowest case fatality ratios, the cost would be $573/DALY. If the vaccine prevents a small proportion of stillbirths, it would be even more cost-effective. Vaccination cost/dose, disease incidence, and case fatality were key drivers of cost/DALY in sensitivity analyses. CONCLUSION: Maternal GBS immunization could be a cost-effective intervention in low-income sub-Saharan Africa, with cost-effectiveness ratios similar to other recently introduced vaccines. The vaccination cost at which introduction is cost-effective depends on disease incidence and vaccine efficacy. Clinical Trial registry name and registration number: Not applicable.
引用
- Russell LB, Kim SY, Cosgriff B, et al. Cost-effectiveness of maternal GBS immunization in low-income sub-Saharan Africa. Vaccine. 2017. PMID: 29129451. doi:10.1016/j.vaccine.2017.07.108
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。